Molecular Mechanisms Underlying Sarcopenia in Heart Failure

Overview

Journal J Cardiovasc Aging

Date 2024 Mar 8

PMID 38455513

Authors

Cody A Rutledge

Affiliations

Soon will be listed here.

Abstract

The loss of skeletal muscle, also known as sarcopenia, is an aging-associated muscle disorder that is disproportionately present in heart failure (HF) patients. HF patients with sarcopenia have poor outcomes compared to the overall HF patient population. The prevalence of sarcopenia in HF is only expected to grow as the global population ages, and novel treatment strategies are needed to improve outcomes in this cohort. Multiple mechanistic pathways have emerged that may explain the increased prevalence of sarcopenia in the HF population, and a better understanding of these pathways may lead to the development of therapies to prevent muscle loss. This review article aims to explore the molecular mechanisms linking sarcopenia and HF, and to discuss treatment strategies aimed at addressing such molecular signals.

Citing Articles

Cancerous Conditions Accelerate the Aging of Skeletal Muscle via Mitochondrial DNA Damage.

Luo Y, Fujiwara-Tani R, Kawahara I, Goto K, Nukaga S, Nishida R Int J Mol Sci. 2024; 25(13).

PMID: 39000167 PMC: 11241065. DOI: 10.3390/ijms25137060.

References

Morley J, Thomas D, Wilson M . Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006; 83(4):735-43. DOI: 10.1093/ajcn/83.4.735. View

Doughan A, Harrison D, Dikalov S . Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res. 2007; 102(4):488-96. DOI: 10.1161/CIRCRESAHA.107.162800. View

Massimino E, Izzo A, Riccardi G, Della Pepa G . The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms. Cells. 2021; 10(8). PMC: 8393336. DOI: 10.3390/cells10081958. View

Gomes M, Lecker S, Jagoe R, Navon A, GOLDBERG A . Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A. 2001; 98(25):14440-5. PMC: 64700. DOI: 10.1073/pnas.251541198. View

Guzman Mentesana G, Baez A, Lo Presti M, Dominguez R, Cordoba R, Bazan C . Functional and structural alterations of cardiac and skeletal muscle mitochondria in heart failure patients. Arch Med Res. 2014; 45(3):237-46. DOI: 10.1016/j.arcmed.2014.03.003. View

Landi F, Marzetti E, Martone A, Bernabei R, Onder G . Exercise as a remedy for sarcopenia. Curr Opin Clin Nutr Metab Care. 2013; 17(1):25-31. DOI: 10.1097/MCO.0000000000000018. View

Xu J, Wan C, Ktoris K, Reijnierse E, Maier A . Sarcopenia Is Associated with Mortality in Adults: A Systematic Review and Meta-Analysis. Gerontology. 2021; 68(4):361-376. DOI: 10.1159/000517099. View

Coen P, Musci R, Hinkley J, Miller B . Mitochondria as a Target for Mitigating Sarcopenia. Front Physiol. 2019; 9:1883. PMC: 6335344. DOI: 10.3389/fphys.2018.01883. View

Xu M, Chen X, Chen D, Yu B, Huang Z . FoxO1: a novel insight into its molecular mechanisms in the regulation of skeletal muscle differentiation and fiber type specification. Oncotarget. 2016; 8(6):10662-10674. PMC: 5354690. DOI: 10.18632/oncotarget.12891. View

10.

Baeuerle P, Henkel T . Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 1994; 12:141-79. DOI: 10.1146/annurev.iy.12.040194.001041. View

11.

Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M . Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized.... J Am Coll Cardiol. 2009; 54(10):919-27. DOI: 10.1016/j.jacc.2009.04.078. View

12.

Mettauer B, Zoll J, Garnier A, Ventura-Clapier R . Heart failure: a model of cardiac and skeletal muscle energetic failure. Pflugers Arch. 2006; 452(6):653-66. DOI: 10.1007/s00424-006-0072-7. View

13.

Rutledge C, Enriquez A, Redding K, Lopez M, Mullett S, Gelhaus S . Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation. Cardiovasc Drugs Ther. 2023; 38(6):1289-1302. PMC: 10788853. DOI: 10.1007/s10557-023-07482-9. View

14.

Lai L, Leone T, Keller M, Martin O, Broman A, Nigro J . Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. Circ Heart Fail. 2014; 7(6):1022-31. PMC: 4241130. DOI: 10.1161/CIRCHEARTFAILURE.114.001469. View

15.

van der Ent M, Jeneson J, Remme W, Berger R, Ciampricotti R, Visser F . A non-invasive selective assessment of type I fibre mitochondrial function using 31P NMR spectroscopy. Evidence for impaired oxidative phosphorylation rate in skeletal muscle in patients with chronic heart failure. Eur Heart J. 1998; 19(1):124-31. DOI: 10.1053/euhj.1997.0727. View

16.

Lv J, Li Y, Shi S, Xu X, Wu H, Zhang B . Skeletal muscle mitochondrial remodeling in heart failure: An update on mechanisms and therapeutic opportunities. Biomed Pharmacother. 2022; 155:113833. DOI: 10.1016/j.biopha.2022.113833. View

17.

Narumi T, Watanabe T, Kadowaki S, Takahashi T, Yokoyama M, Kinoshita D . Sarcopenia evaluated by fat-free mass index is an important prognostic factor in patients with chronic heart failure. Eur J Intern Med. 2015; 26(2):118-22. DOI: 10.1016/j.ejim.2015.01.008. View

18.

Bacurau A, Cunha T, Souza R, Voltarelli V, Gabriel-Costa D, Brum P . Aerobic Exercise and Pharmacological Therapies for Skeletal Myopathy in Heart Failure: Similarities and Differences. Oxid Med Cell Longev. 2016; 2016:4374671. PMC: 4745416. DOI: 10.1155/2016/4374671. View

19.

Konishi M, Kagiyama N, Kamiya K, Saito H, Saito K, Ogasahara Y . Impact of sarcopenia on prognosis in patients with heart failure with reduced and preserved ejection fraction. Eur J Prev Cardiol. 2021; 28(9):1022-1029. DOI: 10.1093/eurjpc/zwaa117. View

20.

Chen S, Czernuszewicz G, Tan Y, Lombardi R, Jin J, Willerson J . Human molecular genetic and functional studies identify TRIM63, encoding Muscle RING Finger Protein 1, as a novel gene for human hypertrophic cardiomyopathy. Circ Res. 2012; 111(7):907-19. PMC: 3482312. DOI: 10.1161/CIRCRESAHA.112.270207. View